- Internal libraries with existing healthcare databanks
- Exhaustive secondary research resource
We believe strongly that an effective growth strategy is one that is formulated with clarity on market conditions, customer demand situation, competitive landscape, regulatory and reimbursement changes and upcoming technology adoption trends. Our capability to design and conduct robust research required to generate credible insights sets the stage for successful growth strategy development.
Clearstate proprietary databases:
External databases we have access to:
Government & advocate opinions
Over 1,000 key opinion leaders who are influencers and drivers of policy making, government initiatives and clinical treatment advocacy.
Over 30,000 medical professionals and hospital management contacts across Emerging Economies covering users, decision maker and key influencers of pharmaceutical, medical devices and solutions.
Over 4,000 supply-side contacts ranging from international to domestics manufacturers and their channel partners in tier 1, 2 and 3 cities in Emerging Economies.
Latest plan to cut medicare drug payments leaves senators skeptical
India's plan for barcodes to track drugs gathers pace
What does Brexit mean for UK health care?
India to start fresh on pharma oversight by reworking 75-year-old law
Fosun to buy KKR-backed Indian drugmaker for up to $1.3 billion
U.S. and UK form global partnership to speed new antibiotics
Sanofi and Boehringer Ingelheim sign contract to $25bn business swap
Human testing of experimental Zika vaccine to begin
Philips acquires Wellcentive, boosts connected care offerings
Samsung and Nestlé team to develop digital platform for better health
Zimmer Biomet rolls out a package of services and tech aimed at ‘value-based’ healthcare
FDA Explains Plans to Use Real-World Data in Medical Device Regulatory Decisions